The 65th installment of the American Society of Hematology (ASH) Annual Meeting will take place December 9-12, 2023 in San Diego, California, and online.
Moffitt's nationally recognized Malignant Hematology Program specializes in the diagnosis and treatment of blood cancers and autoimmune disorders, and we are dedicated to providing exceptional care by developing a tailored treatment plan for each patient. This year, Moffitt authors are listed on 185 abstracts that showcased the latest advances in hematology. In total, there are 58 oral and 104 poster presentations presented by Moffitt authors, six scientific symposia featuring Moffitt speakers.
Be sure to visit our Booth #655 to meet members of the team and learn more about the impact Moffitt is making in cancer research, outcomes and advancements.
To learn more about Moffitt's research and breakthroughs, follow Moffitt on Twitter (@MoffittNews) and LinkedIn or subscribe to our newsletters.
2023 Featured Articles
Already Approved Drug Shows Promise in Patients with MDS/MPN Overlapping Syndromes
Moffitt launched trial investigates myelofibrosis drug in rare patient population
New Study Shows Promise in Equalizing Outcomes for Transplant Patients
Post-transplant drug has potential to close racial gap for mismatched donors
Using Contemporary Data to Better Classify Blood Clot Risk in Polycythemia Vera Patients
Study shows age is less of a factor than medical history when it comes to risk for thrombosis
Identifying Inflammatory Markers Related to Toxicities Early Can Improve Multiple Myeloma Treatment
Understanding the immune landscape of CAR T-related toxicities and responses can improve outcomes
New Treatment Reduces Need for Blood Transfusions for Patients with Certain Blood Cancers, Study Shows
Almost 40% of patients with lower risk myelodysplastic syndromes achieved eight-week transfusion independence with imetelstat, study shows
Press Contact
2022 Videos
Stay Tuned for 2023 Updates
Business of Biotech
Conference Information, RegistrationMoffitt Resources
